Literature DB >> 18077184

Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET.

Koen Van Laere1, Karolien Goffin, Cindy Casteels, Patrick Dupont, Luc Mortelmans, Jan de Hoon, Guy Bormans.   

Abstract

The endocannabinoid system (ECS) is implicated as a regulator of homeostasis of several cerebral functions and is a novel target for drug treatment of neuropyschiatric disorders. So far, the cerebral cannabinoid-type 1 receptor (CB1R) has only been studied using in vitro, animal model, electrophysiological and post-mortem data. We have used positron emission tomography (PET) using a high-affinity, subtype-selective radioligand, [(18)F]MK-9470, to assess the in vivo cerebral CB1R distribution and its variation with healthy aging and gender. Fifty healthy volunteers (25 M/25 F, 18-69 years) underwent [(18)F]MK-9470 PET. Parametric [(18)F]MK-9470 binding maps were constructed, corrected for partial volume effects and analyzed using statistical parametric mapping in a combined categorical (gender) and covariate (age) design. We found that [(18)F]MK-9470 binding to CB1R increased with aging but only in women (p(FWE)<0.05, corrected for multiple comparisons); this was most pronounced in the basal ganglia, lateral temporal cortex and limbic system, especially in the hippocampus. Men showed higher [(18)F]MK-9470 binding then women (p<0.001, uncorrected), in clusters of the limbic system and cortico-striato-thalamic-cortical circuit. Region-dependent and gender-related upregulation of [(18)F]MK-9470 binding with aging is in line with ex vivo findings in rodent studies and may be associated with a changing homeostatic capacity or compensation mechanisms in the ECS that is modulated by sex hormones. In vivo PET of the CB1R will likely improve our understanding of the ECS in several neurological and psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077184     DOI: 10.1016/j.neuroimage.2007.10.053

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  50 in total

1.  Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences.

Authors:  Marc D Normandin; Ming-Qiang Zheng; Kuo-Shyan Lin; N Scott Mason; Shu-Fei Lin; Jim Ropchan; David Labaree; Shannan Henry; Wendol A Williams; Richard E Carson; Alexander Neumeister; Yiyun Huang
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-01       Impact factor: 6.200

Review 2.  Sexually-dimorphic alterations in cannabinoid receptor density depend upon prenatal/early postnatal history.

Authors:  Diana Dow-Edwards; Ashley Frank; Dean Wade; Jeremy Weedon; Sari Izenwasser
Journal:  Neurotoxicol Teratol       Date:  2016-09-12       Impact factor: 3.763

3.  Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain.

Authors:  Sandra Marina Sanabria-Bohórquez; Terence G Hamill; Karolien Goffin; Inge De Lepeleire; Guy Bormans; H Donald Burns; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-24       Impact factor: 9.236

4.  Brain PET Poster Sessions PP01-M01 to PP02-N07.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

5.  Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.

Authors:  Jenny Ceccarini; Cindy Casteels; Rawaha Ahmad; Melissa Crabbé; Laura Van de Vliet; Heleen Vanhaute; Mathieu Vandenbulcke; Wim Vandenberghe; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-24       Impact factor: 9.236

Review 6.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

Review 7.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

8.  Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands.

Authors:  Garth E Terry; Jussi Hirvonen; Jeih-San Liow; Sami S Zoghbi; Robert Gladding; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Sean R Donohue; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

9.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

10.  In vivo SPECT and ex vivo autoradiographic brain imaging of the novel selective CB1 receptor antagonist radioligand [125I]SD7015 in CB1 knock-out and wildtype mouse.

Authors:  Domokos Máthé; Ildikó Horváth; Krisztián Szigeti; Sean R Donohue; Victor W Pike; Zisheng Jia; Catherine Ledent; Miklós Palkovits; Tamás F Freund; Christer Halldin; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2013-01-11       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.